NY-CIRIUM
23.8.2022 14:02:54 CEST | Business Wire | Press release
Cirium, the aviation analytics firm, has announced that former Spirit Airlines CEO, Ben Baldanza and former Indigo CCO, Willy Boulter have joined the Cirium On-Time Performance (OTP) Advisory Board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005442/en/
Cirium is the first and only company that has an OTP Advisory Board in the aviation industry. The Board comprises a collaborative team of external advisors who support Cirium’s OTP Program and reports global Annual and Monthly airline and airport on-time analyses.
“We are delighted to welcome Ben and Willy to the Cirium OTP Advisory Board. Together they bring nearly 80 years of aviation experience to the Board, which will be invaluable for Cirium’s airline and airport OTP Program. They will provide key focus and direction on the big-picture initiatives,” said Jeremy Bowen , CEO at Cirium.
Ben Baldanza is a transformational leader in the US airline industry. He was president and CEO for Spirit Airlines and changed that airline into an ultra-low-cost-airline carrier. Prior to Spirit he held executive roles with US Airways, Continental Airlines and TACA Airlines.
In addition to the Cirium OTP Board, Baldanza currently serves on the Board of Directors for JetBlue Airways, Six Flags Entertainment and several private companies. He also co-hosts a weekly podcast that is now in the top 1% of all podcasts by weekly listeners. Baldanza has also been twice named as one of the industry’s 25 Most Influential Leaders .
Baldanza said: “Airline and airport operational performance is increasingly important as the industry recovers from the pandemic and contends with rising challenges such as forecasting travel demand. Cirium’s OTP Program measures the carriers’ and airports’ operational efficiencies and is the standard for on-time arrival and departure benchmarking.”
Willy Boulter has 40 years’ experience in the airline industry, most recently as CCO at India’s largest airline IndiGo. Prior to IndiGo, Boulter was CCO in the Emirates-sponsored team that turned around TAAG Angola Airlines. He held executive roles at Gulf Air, Etihad Airways, low-cost carrier Sky Express, Virgin Atlantic and Cathay Pacific. Boulter also served in the British Army in the UK, Canada and Hong Kong and is a fellow of the Royal Aeronautical Society.
Boulter said: “It’s a privilege to join the Cirium OTP Advisory Board to help steer an accurate analysis of airline and airport operations. The program has multiple benefits for the industry, not least enabling improved operational performance and tracking aircraft utilization aligned to sustainability targets.”
Baldanza and Boulter join Luis Felipe de Oliveira , Director General at ACI World and Henry H. Harteveldt, President – Travel Industry Analyst at Atmosphere Research Group on the Board.
Click here to download the latest Cirium On-Time Performance Monthly Report.
Ends
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005442/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom